

Aubagne, France | March 25, 2025

Resolutions of the Combined Annual Shareholders' Meeting of Sartorius Stedim Biotech S.A.

At today's combined Annual Shareholders' Meeting of Sartorius Stedim Biotech S.A., shareholders granted discharge to all Directors by a large majority.

The shareholders elected Cécile Dussart and Christopher Nowers as new Board Members. To ensure staggering of office terms, both were appointed for three years while Joachim Kreuzburg was reappointed for two years and René Fáber, Pascale Boissel and Lothar Kappich for four years.

Henri Riey, who served on the Board since 2007, decided not to seek re-election. The Board sincerely thanked him for his valuable contributions and expertise over nearly two decades.

Effective March 25, 2025, the Board of Directors of Sartorius Stedim Biotech S.A. is composed of: Joachim Kreuzburg (Chairman), René Fáber (CEO), Pascale Boissel, Susan Dexter, Cécile Dussart, Romaine Fernandes (Director Representing Employees), Anne-Marie Graffin (Lead Independent Director), Lothar Kappich, and Christopher Nowers.

The shareholders also approved all other resolutions by a large majority, including the proposal to pay a dividend of 0.69 euros per share for fiscal 2024. The total payout will be 67.1 million euros. The dividend will be paid as from April 4, 2025.

Further Information

[Shareholders' Meeting | Sartorius Stedim Biotech S.A.](#)

[Company images](#)

[CVs and images of the Directors](#)

Financial calendar

April 16, 2025	Publication of the first quarter results January to March 2025
July 22, 2025	Publication of the half-year results January to June 2025
October 16, 2025	Publication of the nine-month results January to September 2025

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications, such as cell and gene therapies, safely, rapidly, and sustainably. The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. The company has a strong global reach

with manufacturing and R&D sites as well as sales entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies. In 2024, the company generated sales revenue of around 2.8 billion euros. Currently, more than 9,900 employees are working for customers around the globe.

Visit our [Newsroom](#) and follow us on [LinkedIn](#).

Contact

Leona Malorny

Head of External Communications

+49 551 308 4067

leona.malorny@sartorius.com